A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

• Status: Completed
• Trial end date: 2021-05-17
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LG Chem
• Treatments: Febuxostat

Criteria

Inclusion Criteria:

1. Subjects or the subject's legally acceptable representatives who sign a written informed consent form prior to the initiation of any study procedures.

2. Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology (ACR) criteria.

Exclusion Criteria:

1. Subjects with secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant).

2. Subjects experiencing an active acute gout attack within 3 weeks prior to screening (Visit 1).